ADMA ADMA BIOLOGICS, INC.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: End-to-end biopharmaceutical company manufacturing specialty biologics for immunodeficient and immune-compromised patients
• • New emphasis on SG-001 for prevention/treatment of S. pneumoniae infections, with pilot batch completed and pre-IND planned in FY 2026

Risk Factors

• • FDA inspections risk: potential issuance of warning letters or enforcement actions due to non-compliance with cGMP at ADMA or third-party contractors
• • Geopolitical exposure: supply chain disruptions and sales impact from Russia-Ukraine conflict and sanctions, plus risks in South America, Northern Africa, Middle East

Management Discussion & Analysis

• • Revenue $510.2M in 2025, up 20% YoY from $426.5M, driven by ASCENIV ($362.5M, +51%), offset by BIVIGAM decline (-14%)
• • Gross margin improved to 57.4% in 2025 vs 51.5% in 2024, due to favorable IG product mix and lower manufacturing costs

What are the latest ADMA SEC filings in 2026?

ADMA BIOLOGICS, INC. (ADMA) has filed a 10-K annual report on February 25, 2026, a 10-Q quarterly report on May 6, 2026, an 8-K current report on June 2, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did ADMA file its most recent 10-K annual report?

ADMA BIOLOGICS, INC. (ADMA) filed its most recent 10-K annual report on February 25, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view ADMA 10-Q quarterly reports?

ADMA BIOLOGICS, INC. (ADMA)'s most recent 10-Q quarterly report was filed on May 6, 2026. SignalX displays every ADMA 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has ADMA filed recently?

ADMA BIOLOGICS, INC. (ADMA)'s most recent 8-K was filed on June 2, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find ADMA insider trading activity (Form 4)?

SignalX aggregates every ADMA Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does ADMA file with the SEC?

ADMA BIOLOGICS, INC. (ADMA) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new ADMA filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for ADMA BIOLOGICS, INC. (ADMA).

What is ADMA's SEC CIK number?

ADMA BIOLOGICS, INC. (ADMA)'s SEC CIK (Central Index Key) number is 1368514. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1368514 to look up all ADMA filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find ADMA return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from ADMA BIOLOGICS, INC. (ADMA) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.